Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.

ABSTRACT:

Background

Blood-based amyloid biomarkers may provide a non-invasive, cost-effective and scalable manner for detecting cerebral amyloidosis in early disease stages.

Methods

In this prospective cross-sectional study, we quantified plasma Aβ_1-42/Aβ_1-40 ratios with both routinely available ELISAs and novel SIMOA Amyblood assays, and provided a head-to-head comparison of their performances to detect cerebral amyloidosis in a nondemented elderly cohort (n = 199). Participants were stratified according to amyloid-PET status, and the performance of plasma Aβ_1-42/Aβ_1-40 to detect cerebral amyloidosis was assessed using receiver operating characteristic analysis. We additionally investigated the correlations of plasma Aβ ratios with amyloid

SUBMITTER: De Meyer S 

PROVIDER: S-EPMC7719262 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature